Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Synthesis and biological evaluation of a peptide-paclitaxel conjugate which targets the integrin αvβ₆.

Li S, Gray BP, McGuire MJ, Brown KC.

Bioorg Med Chem. 2011 Sep 15;19(18):5480-9. doi: 10.1016/j.bmc.2011.07.046. Epub 2011 Aug 4.

2.

Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.

Chen X, Plasencia C, Hou Y, Neamati N.

J Med Chem. 2005 Feb 24;48(4):1098-106. Erratum in: J Med Chem. 2005 Sep 8;48(18):5874.

PMID:
15715477
3.

Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.

Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C.

Chemistry. 2015 Apr 27;21(18):6921-9. doi: 10.1002/chem.201500158. Epub 2015 Mar 17.

PMID:
25784522
4.

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.

Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T, Sakagami H, Furutani T, Doihara H, Kudoh M, Kuromitsu S.

Mol Cancer Ther. 2014 Feb;13(2):329-40. doi: 10.1158/1535-7163.MCT-13-0395. Epub 2014 Jan 13.

5.

Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.

Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3459-69.

6.

Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.

Wang S, Han X, Wang J, Yao J, Shi Y.

PLoS One. 2014 Mar 4;9(3):e89848. doi: 10.1371/journal.pone.0089848. eCollection 2014.

7.

Synergistic antitumor effect of α-pinene and β-pinene with paclitaxel against non-small-cell lung carcinoma (NSCLC).

Zhang Z, Guo S, Liu X, Gao X.

Drug Res (Stuttg). 2015 Apr;65(4):214-8. doi: 10.1055/s-0034-1377025. Epub 2014 Sep 4.

PMID:
25188609
8.

2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.

Peng L, Schorzman AN, Ma P, Madden AJ, Zamboni WC, Benhabbour SR, Mumper RJ.

Int J Nanomedicine. 2014 Jul 30;9:3601-10. doi: 10.2147/IJN.S66040. eCollection 2014.

9.
10.

Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications.

Li S, McGuire MJ, Lin M, Liu YH, Oyama T, Sun X, Brown KC.

Mol Cancer Ther. 2009 May;8(5):1239-49. doi: 10.1158/1535-7163.MCT-08-1098. Epub 2009 May 12.

11.

In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.

Ryppa C, Mann-Steinberg H, Biniossek ML, Satchi-Fainaro R, Kratz F.

Int J Pharm. 2009 Feb 23;368(1-2):89-97. doi: 10.1016/j.ijpharm.2008.09.055. Epub 2008 Oct 17.

PMID:
18992308
12.

Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.

Xie CY, Xu YP, Jin W, Lou LG.

Anticancer Drugs. 2012 Aug;23(7):698-705. doi: 10.1097/CAD.0b013e328352cc10.

PMID:
22441567
13.
14.

Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery.

Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F, Burreddu P, Carta P, Rassu G, Perego P, Carenini N, Zunino F, De Cesare M, Castiglioni V, Scanziani E, Scolastico C, Casiraghi G, Zanardi F, Manzoni L.

Bioconjug Chem. 2012 Aug 15;23(8):1610-22. doi: 10.1021/bc300164t. Epub 2012 Jul 20.

PMID:
22770429
15.

Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.

Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, Wang CH, Yeh KY.

Lung Cancer. 2008 Feb;59(2):180-91. Epub 2007 Sep 27.

PMID:
17900752
16.

Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.

Aftab BT, Dobromilskaya I, Liu JO, Rudin CM.

Cancer Res. 2011 Nov 1;71(21):6764-72. doi: 10.1158/0008-5472.CAN-11-0691. Epub 2011 Sep 6.

17.

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.

Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.

18.

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA.

J Med Chem. 1999 Nov 18;42(23):4919-24.

PMID:
10579854
19.

Design and synthesis of de novo cytotoxic alkaloids by mimicking the bioactive conformation of paclitaxel.

Sun L, Veith JM, Pera P, Bernacki RJ, Ojima I.

Bioorg Med Chem. 2010 Oct 1;18(19):7101-12. doi: 10.1016/j.bmc.2010.07.069. Epub 2010 Aug 6.

20.

Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation.

Dosio F, Reddy LH, Ferrero A, Stella B, Cattel L, Couvreur P.

Bioconjug Chem. 2010 Jul 21;21(7):1349-61. doi: 10.1021/bc100154g.

PMID:
20597546

Supplemental Content

Support Center